June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment
Author Affiliations & Notes
  • Pear Pongsachareonnont
    Ophthalmology, Chulalongkorn University and King Chulalongkorn Memorial hospital , Bangkok, Bangkok, Thailand
  • wai ching Lam
    Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
    Ophthalmology , University of Hongkon, Hongkong, Hong Kong
  • Michael Ying Kit Mak
    Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships   Pear Pongsachareonnont, Bayer (F); wai ching Lam, Bayer (F); Michael Ying Kit Mak, Bayaer (F)
  • Footnotes
    Support  Global ophthalmology award by Bayer
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3205. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Pear Pongsachareonnont, wai ching Lam, Michael Ying Kit Mak; Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3205.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate cytokines level in aqueous humor of ranibizumab (RN) non-responders with neovascular AMD (nAMD) who were treated with either combination of ranibizumab (RN), and photodynamic therapy (PDT) or aflibercept (AF) and explore the prediction cytokines for RN non-responders

Methods : This prospective study collected aqueous specimen prospectively from RN non-responder receiving either AF or combination PDT (Study gr.) and RN responders patients (Control gr.) for cytokine analysis at baseline, month 1, 2 and 3 visit of treatment. Cytokines level and changes in 3 treatment groups were compared by using GLMM. Weighted propensity score was used to adjusted for covariate. VEGF, PDGF,PLGF and others angiogenesis/inflammatory cytokines were analyzed by Bio-Plex® Multiplex Immunoassays.

Results : Eleven, 8 and 13 eyes received AF treatment, combined PDT, and control respectively. Mean change of visual acuity from baseline is improved [WC1] in the control gr. (P<0.05) while study gr. didn’t show significant changes. In PDT group, 75% of patients showed stabilization or improvement in AMD clinical activity while PLGF, PDGF and leptin level are significant increase at first month: At 2 months visit, VEGF-A level is increase while Endoglin and HB-EGF decline when compare to baseline. At 3 months visit, VEGF-C and HGF concentration are higher in AF group than control group (p=0.02 and 0.02). There are no different in PLGF,PDGF,VEGF-A levels between each treatment group in all visit. PLGF level was higher in study gr. while IL-7 was lower in study gr. (P=0.02 and 0.04 respectively). The combination level of Angiopoetin 2, IL-6, ICAM, Follistatin and IL-3 can predict the response of RN treatment with 83% sensitivity and 72% specificity.

Conclusions : Switching to AF may not reduce major cytokines level but resulted in improvement of visual acuity. Combination of PDT and RN resulted increase angiogenesis cytokines. The lack of IL-7 was found in non-responder patient. Apart from cytokine levels, other factors such as cytokine receptors and immune system activity may play a role in non-response patient.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×